Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas

✍ Scribed by Meike Körner; Beatrice Waser; Jean Claude Reubi

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: French
• Weight: 641 KB
• Volume: 115
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.20948

✦ Synopsis

Abstract

Numerous peptide receptors are overexpressed in human cancer, permitting in vivo tumor targeting. Among such receptors, those for the neurotransmitter neuropeptide Y (NPY) are overexpressed in various tumors. Since NPY can play a role in the kidney, NPY receptor expression and/or endogenous production of peptides of the NPY family (NPY, PYY, PP) were evaluated in 40 renal cell carcinomas (RCCs) and 18 nephroblastomas. NPY receptor protein expression was investigated by in vitro autoradiography using ^125^I‐labeled PYY in competition with NPY receptor subtype‐selective analogs. NPY, PYY and PP production was assessed immunohistochemically. Fifty‐six percent of RCCs expressed the Y1 receptor subtype in moderate density, and 80% of nephroblastomas expressed Y1 and Y2 subtypes in moderate to high density. Y1 was also highly expressed in intratumoral blood vessels. In selected cases, NPY was observed in nerve fibers in close association with intratumoral blood vessels and in the vicinity of tumor cells, while no PYY or PP was detected immunohistochemically in these sites. NPY receptors on renal tumor cells and tumor blood vessels may therefore be the molecular targets of endogenous NPY released by intratumoral nerve fibers. With regard to clinical applications, NPY receptors may act as in vivo targets for receptor‐directed therapy of RCCs and nephroblastomas for which alternative therapeutic approaches are still required. © 2005 Wiley‐Liss, Inc.